No retraction, correction or concern found when last checked on Oct 19, 2026.

Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer

Hui Zhou, Liyong Zhu, Jun Song and 9 more

Molecular Cancer · 2022 · Review · CC BY

doi:10.1186/s12943-022-01556-2

Read free

Abstract

Supplementary Information. The online version contains supplementary material available at 10.1186/s12943-022-01556-2.

References 258

1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
Not in our library10.3322/caac.21660
2.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683-691.
Not in our library10.1136/gutjnl-2015-310912
3.
Pantel K, Alix-Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16:398-406.
Not in our library10.1016/j.molmed.2010.07.001
4.
Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K. What's new on circulating tumor cells? A meeting report. Breast Cancer Res. 2010;12:307-307.
Not in our library10.1186/bcr2601
5.
Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of Cancer. Clin Chem. 2013;59:110-118.
Not in our library10.1373/clinchem.2012.194258
6.
Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869;14:146-149.
Not in our library
7.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791.
Not in our library10.1056/nejmoa040766
8.
Röcken M. Early tumor dissemination, but late metastasis: insights into tumor dormancy. J Clin Invest. 2010;120:1800-1803.
Not in our library10.1172/jci43424
9.
Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M, Diéras V, Rolland E, Mignot L, Mathiot C, Bidard FC. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol. 2012;23:618-624.
Not in our library10.1093/annonc/mdr263
10.
Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32:479-484.
Not in our library10.1038/nbt.2892
11.
Jiang R, Lu YT, Ho H, Li B, Chen JF, Lin M, Li F, Wu K, Wu H, Lichterman J, et al. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer. Oncotarget. 2015;6:44781-44793.
Not in our library10.18632/oncotarget.6330
12.
Mandel P, Metais P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil. 1948;142:241-243.
Not in our library
13.
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646-650.
Not in our library
14.
Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994;54:3568-3573.
Not in our library
15.
Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999;59:67-70.
Not in our library
16.
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14:985-990.
Not in our library10.1038/nm.1789
17.
S ELA, Mäger I, Breakefield XO, Wood MJ: extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12:347–57.
Not in our library10.1038/nrd3978
18.
Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem. 1987;262:9412-9420.
Not in our library
19.
Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ. B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996;183:1161-1172.
Not in our library10.1084/jem.183.3.1161
20.
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998;4:594-600.
Not in our library10.1038/nm0598-594
21.
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
Not in our library10.1126/science.aau6977
22.
George JN. Platelets. Lancet. 2000;355:1531-1539.
Not in our library10.1016/s0140-6736(00)02175-9
23.
van der Meijden PEJ, Heemskerk JWM. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. 2019;16:166-179.
Not in our library10.1038/s41569-018-0110-0
24.
McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014;16:717-727.
Not in our library10.1038/ncb3015
25.
Trousseau A. Clinique medicale de l'hotel Dieu de Paris quatrieme edition. Medical clinic at Dieu's hotel in Paris. 1873;3.
Not in our library
26.
Wright JH. The origin and nature of the blood plates. Boston Med Surg J. 1906;154:643-645.
Not in our library
27.
Nilsson RJ, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M, Widmark A, Gerritsen WR, Verheul HM, Vandertop WP, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood. 2011;118:3680-3683.
Not in our library10.1182/blood-2011-03-344408
28.
RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics · 2015
No notice
29.
Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35:1216-1224.
Not in our library10.1038/onc.2015.192
30.
Tsai WS, You JF, Hung HY, Hsieh PS, Hsieh B, Lenz HJ, Idos G, Friedland S, Yi-Jiun Pan J, Shao HJ, et al. Novel circulating tumor cell assay for detection of colorectal adenomas and Cancer. Clin Transl Gastroenterol. 2019;10:e00088.
Not in our library10.14309/ctg.0000000000000088
31.
Bork U, Rahbari NN, Schölch S, Reissfelder C, Kahlert C, Büchler MW, Weitz J, Koch M. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015;112:1306-1313.
Not in our library10.1038/bjc.2015.88
32.
Hinz S, Röder C, Tepel J, Hendricks A, Schafmayer C, Becker T, Kalthoff H. Cytokeratin 20 positive circulating tumor cells are a marker for response after neoadjuvant chemoradiation but not for prognosis in patients with rectal cancer. BMC Cancer. 2015;15:953.
Not in our library10.1186/s12885-015-1989-z
33.
Pan RJ, Hong HJ, Sun J, Yu CR, Liu HS, Li PY, Zheng MH. Detection and clinical value of circulating tumor cells as an assisted prognostic marker in colorectal Cancer patients. Cancer Manag Res. 2021;13:4567-4578.
Not in our library10.2147/cmar.s300554
34.
Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer. · 2021
Not checked
35.
Tan Y, Wu H. The significant prognostic value of circulating tumor cells in colorectal cancer: a systematic review and meta-analysis. Curr Probl Cancer. 2018;42:95-106.
Not in our library10.1016/j.currproblcancer.2017.11.002
36.
Groot Koerkamp B, Rahbari NN, Büchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20:2156-2165.
Not in our library10.1245/s10434-013-2907-8
37.
Connor AA, McNamara K, Al-Sukhni E, Diskin J, Chan D, Ash C, Lowes LE, Allan AL, Zogopoulos G, Moulton CA, Gallinger S. Central, but not peripheral, circulating tumor cells are prognostic in patients undergoing resection of colorectal Cancer liver metastases. Ann Surg Oncol. 2016;23:2168-2175.
Not in our library10.1245/s10434-015-5038-6
38.
Zhao JX, Liu LR, Yang XY, Liu F, Zhang ZG. Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients. Oncotarget. 2017;8:67918-67932.
Not in our library10.18632/oncotarget.18912
39.
Wu F, Zhu J, Mao Y, Li X, Hu B, Zhang D. Associations between the epithelial-mesenchymal transition phenotypes of circulating tumor cells and the Clinicopathological features of patients with colorectal Cancer. Dis Markers. 2017;2017:9474532.
Not in our library10.1155/2017/9474532
40.
Zhong Y, Ma T, Qiao T, Hu H, Li Z, Luo K, Wang Y, Tang Q, Wang G, Huang R, Wang X. Role of phenotypes of circulating tumor cells in the diagnosis and treatment of colorectal Cancer. Cancer Manag Res. 2021;13:7077-7085.
Not in our library10.2147/cmar.s316544
41.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-413.
Not in our library10.1126/science.aan6733
42.
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441-1448.
Not in our library10.1038/s41591-018-0134-3
43.
Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients · 2019
No notice
44.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373:1627-1639.
Not in our library10.1056/nejmoa1507643
45.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
Not in our library10.1056/nejmoa1500596
46.
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. Safety and efficacy of Pembrolizumab monotherapy in patients with previously treated advanced gastric and Gastroesophageal junction Cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013.
Not in our library10.1001/jamaoncol.2018.0013
47.
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients · 2016
No notice
48.
Raimondi L, Raimondi FM, Di Benedetto L, Cimino G, Spinelli GP. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer. Int J Mol Sci. 2020;21:6907.
Not in our library10.3390/ijms21186907
49.
Songdong Meng DT, Eugene P. Frenkel: circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10:8152-8162.
Not in our library10.1158/1078-0432.ccr-04-1110
50.
Kowalik A, Kowalewska M, Góźdź S. Current approaches for avoiding the limitations of circulating tumor cells detection methods-implications for diagnosis and treatment of patients with solid tumors. Transl Res. 2017;185:58-84.e15.
Not in our library10.1016/j.trsl.2017.04.002
51.
Yin CQ, Yuan CH, Qu Z, Guan Q, Chen H, Wang FB. Liquid biopsy of hepatocellular carcinoma: circulating tumor-derived biomarkers. Dis Markers. 2016;2016:1427849.
Not in our library10.1155/2016/1427849
52.
Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LWMM, Uhr JW. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci. 1998;95:4589-4594.
Not in our library10.1073/pnas.95.8.4589
53.
A Review of Circulating Tumour Cell Enrichment Technologies · 2021
No notice
54.
Bahnassy AA, Salem SE, Mohanad M, Abulezz NZ, Abdellateif MS, Hussein M, Zekri CAN, Zekri AN, Allahloubi NMA. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, Cell Search, Quantitative Real-time PCR and Cytomorphology). Exp Mol Pathol. 2019;106:90-101.
Not in our library10.1016/j.yexmp.2018.12.006
55.
Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235-1239.
Not in our library10.1038/nature06385
56.
Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015;12:685-691.
Not in our library10.1038/nmeth.3404
57.
Li W, Wang H, Zhao Z, Gao H, Liu C, Zhu L, Wang C, Yang Y. Emerging nanotechnologies for liquid biopsy: the detection of circulating tumor cells and extracellular vesicles. Adv Mater. 2019;31:e1805344.
Not in our library10.1002/adma.201805344
58.
Wang R, Chu GCY, Mrdenovic S, Annamalai AA, Hendifar AE, Nissen NN, Tomlinson JS, Lewis M, Palanisamy N, Tseng HR, et al. Cultured circulating tumor cells and their derived xenografts for personalized oncology. Asian J Urol. 2016;3:240-253.
Not in our library10.1016/j.ajur.2016.08.005
59.
Muluhngwi P, Valdes R, Fernandez-Botran R, Burton E, Williams B, Linder MW. Cell-free DNA diagnostics: current and emerging applications in oncology. Pharmacogenomics. 2019;20:357-380.
Not in our library10.2217/pgs-2018-0174
60.
Spindler KG. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer. Acta Oncol. 2017;56:7-16.
Not in our library10.1080/0284186x.2016.1253861
61.
Vymetalkova V, Cervena K, Bartu L, Vodicka P. Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review. Int J Mol Sci. 2018;19:3356.
Not in our library10.3390/ijms19113356
62.
Yang Y-C, Wang D, Jin L, Yao H-W, Zhang J-H, Wang J, Zhao X-M, Shen C-Y, Chen W, Wang X-L, et al. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients. Biosci Rep. 2018;38:BSR20180322.
Not in our library10.1042/bsr20180322
63.
Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer · 2019
No notice
64.
Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III Colon Cancer. JAMA Oncol. 2019;5:1710-1717.
Not in our library10.1001/jamaoncol.2019.3616
65.
Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9:eaan2415.
Not in our library10.1126/scitranslmed.aan2415
66.
Agah S, Akbari A, Talebi A, Masoudi M, Sarveazad A, Mirzaei A, Nazmi F. Quantification of plasma cell-free circulating DNA at different stages of colorectal Cancer. Cancer Investig. 2017;35:625-632.
Not in our library10.1080/07357907.2017.1408814
67.
Bedin C, Enzo MV, Del Bianco P, Pucciarelli S, Nitti D, Agostini M. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer. 2017;140:1888-1898.
Not in our library10.1002/ijc.30565
68.
Kobayashi S, Nakamura Y, Taniguchi H, Odegaard JI, Nomura S, Kojima M, Sugimoto M, Konishi M, Gotohda N, Takahashi S, Yoshino T. Impact of preoperative circulating tumor DNA status on survival outcomes after hepatectomy for Resectable colorectal liver metastases. Ann Surg Oncol. 2021;28:4744-4755.
Not in our library10.1245/s10434-020-09449-8
69.
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study · 2021
No notice
70.
Detection of tumor‐derived cell‐free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid · 2021
Not checked
71.
Yu H, Han L, Yuan J, Sun Y. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer. Cancer Biomark. 2020;27:29-37.
Not in our library10.3233/cbm-182344
72.
Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet. 1996;30:441-464.
Not in our library10.1146/annurev.genet.30.1.441
73.
Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, et al. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020;12:eaax7533.
Not in our library10.1126/scitranslmed.aax7533
74.
Nassar FJ, Msheik ZS, Nasr RR, Temraz SN. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction. Clin Epigenetics. 2021;13:111.
Not in our library10.1186/s13148-021-01095-5
75.
Jin S, Zhu D, Shao F, Chen S, Guo Y, Li K, Wang Y, Ding R, Gao L, Ma W, et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc Natl Acad Sci U S A. 2021;1188:e2017421118.
Not in our library10.1073/pnas.2017421118
76.
Bach S, Paulis I, Sluiter NR, Tibbesma M, Martin I, van de Wiel MA, Tuynman JB, Bahce I, Kazemier G, Steenbergen RDM. Detection of colorectal cancer in urine using DNA methylation analysis. Sci Rep. 2021;11:2363.
Not in our library10.1038/s41598-021-81900-6
77.
Thomsen CB, Hansen TF, Andersen RF, Lindebjerg J, Jensen LH, Jakobsen A. Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. Ther Adv Med Oncol. 2020;12:1758835920918472.
Not in our library10.1177/1758835920918472
78.
Liu L, Toung JM, Jassowicz AF, Vijayaraghavan R, Kang H, Zhang R, Kruglyak KM, Huang HJ, Hinoue T, Shen H, et al. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. Ann Oncol. 2018;29:1445-1453.
Not in our library10.1093/annonc/mdy119
79.
Wu X, Zhang Y, Hu T, He X, Zou Y, Deng Q, Ke J, Lian L, He X, Zhao D, et al. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer. Mol Oncol. 2021;15:2702-2714.
Not in our library10.1002/1878-0261.12942
80.
Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomatà C, Binder AM, Cristiano C, et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. 2018;67:1995-2005.
Not in our library10.1136/gutjnl-2016-313372
81.
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, Castaños-Vélez E, Blumenstein BA, Rösch T, Osborn N, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317-325.
Not in our library10.1136/gutjnl-2012-304149
82.
deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J, Steiger KV, Grützmann R, Pilarsky C, Habermann JK, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009;55:1337-1346.
Not in our library10.1373/clinchem.2008.115808
83.
Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer · 2011
No notice
84.
Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33:1809-1824.
Not in our library10.1200/jco.2014.59.7633
85.
Yu IS, Cheung WY. Metastatic colorectal Cancer in the era of personalized medicine: a more tailored approach to systemic therapy. Can J Gastroenterol Hepatol. 2018;2018:9450754.
Not in our library10.1155/2018/9450754
86.
Schraa SJ, van Rooijen KL, van der Kruijssen DEW, Rubio Alarcón C, Phallen J, Sausen M, Simmons J, Coupé VMH, van Grevenstein WMU, Elias S, et al. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study. BMC Cancer. 2020;20:790.
Not in our library10.1186/s12885-020-07252-y
87.
Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K, Shirasu H, Ebi H, Yamanaka T, Aleshin A, et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021;112:2915-2920.
Not in our library10.1111/cas.14926
88.
French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14:3408-3415.
Not in our library10.1158/1078-0432.ccr-07-1489
89.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532-536.
Not in our library10.1038/nature11156
90.
Yamada T, Iwai T, Takahashi G, Kan H, Koizumi M, Matsuda A, Shinji S, Yamagishi A, Yokoyama Y, Tatsuguchi A, et al. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer. Cancer Sci. 2016;107:936-943.
Not in our library10.1111/cas.12959
91.
Denis JA, Lacorte JM. Detection of RAS mutations in circulating tumor cells: applications in colorectal cancer and prospects. Ann Biol Clin (Paris). 2017;75:607-618.
Not in our library10.1684/abc.2017.1304
92.
Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA. · 2017
Not checked
93.
Kim TW, Peeters M, Thomas A, Gibbs P, Hool K, Zhang J, Ang AL, Bach BA, Price T. Impact of emergent circulating tumor DNA RAS mutation in Panitumumab-treated Chemoresistant metastatic colorectal Cancer. Clin Cancer Res. 2018;24:5602-5609.
Not in our library10.1158/1078-0432.ccr-17-3377
94.
Dumbrava EI, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, et al. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open. 2021;6:100230.
Not in our library10.1016/j.esmoop.2021.100230
95.
Hofman P, Heeke S, Alix-Panabieres C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol. 2019;30:1448-1459.
Not in our library10.1093/annonc/mdz196
96.
Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade · 2014
No notice
97.
Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21:795-801.
Not in our library10.1038/nm.3870
98.
Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, et al. Patient-specific circulating tumor DNA detection during Neoadjuvant chemotherapy in triple-negative breast Cancer. Clin Chem. 2017;63:691-699.
Not in our library10.1373/clinchem.2016.262337
99.
Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 2017;28:1996-2001.
Not in our library10.1093/annonc/mdx212
100.
Kitahara M, Hazama S, Tsunedomi R, Takenouchi H, Kanekiyo S, Inoue Y, Nakajima M, Tomochika S, Tokuhisa Y, Iida M, et al. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer. Cancer Sci. 2016;107:1825-1829.
Not in our library10.1111/cas.13085
101.
Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res. 2019;25:7035-7045.
Not in our library10.1158/1078-0432.ccr-19-1324
102.
Tieng FYF, Abu N, Lee L-H, Ab Mutalib NS. Microsatellite Instability in Colorectal Cancer Liquid Biopsy-Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker. Diagnostics (Basel, Switzerland). 2021;11:544.
Not in our library10.3390/diagnostics11030544
103.
Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44-56.
Not in our library10.1093/annonc/mdy495
104.
Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16:2598-2608.
Not in our library10.1158/1535-7163.mct-17-0386
105.
Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell. 2017;31:172-179.
Not in our library10.1016/j.ccell.2017.01.002
106.
Zhang BO, Xu CW, Shao Y, Wang HT, Wu YF, Song YY, Li XB, Zhang Z, Wang WJ, Li LQ, Cai CL. Comparison of droplet digital PCR and conventional quantitative PCR for measuring EGFR gene mutation. Exp Ther Med. 2015;9:1383-1388.
Not in our library10.3892/etm.2015.2221
107.
Markou A, Tzanikou E, Ladas I, Makrigiorgos GM, Lianidou E. Nuclease-assisted minor allele enrichment using overlapping probes-assisted amplification-refractory mutation system: an approach for the improvement of amplification-refractory mutation system-polymerase chain reaction specificity in liquid biopsies. Anal Chem. 2019;91:13105-13111.
Not in our library10.1021/acs.analchem.9b03325
108.
Lang AH, Drexel H, Geller-Rhomberg S, Stark N, Winder T, Geiger K, Muendlein A. Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn. 2011;13:23-28.
Not in our library10.1016/j.jmoldx.2010.11.007
109.
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4:136ra168.
Not in our library10.1126/scitranslmed.3003726
110.
Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108:9530-9535.
Not in our library10.1073/pnas.1105422108
111.
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20:548-554.
Not in our library10.1038/nm.3519
112.
Corcoran RB, Chabner BA. Application of cell-free DNA analysis to Cancer treatment. N Engl J Med. 2018;379:1754-1765.
Not in our library10.1056/nejmra1706174
113.
Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management · 2018
No notice
114.
van der Pol Y, Mouliere F. Toward the early detection of Cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA. Cancer Cell. 2019;36:350-368.
Not in our library10.1016/j.ccell.2019.09.003
115.
Zhang H, Liu R, Yan C, Liu L, Tong Z, Jiang W, Yao M, Fang W, Chen Z. Advantage of next-generation sequencing in dynamic monitoring of circulating tumor DNA over droplet digital PCR in Cetuximab treated colorectal Cancer patients. Transl Oncol. 2019;12:426-431.
Not in our library10.1016/j.tranon.2018.11.015
116.
Next-generation sequencing in liquid biopsy: cancer screening and early detection · 2019
No notice
117.
Ye P, Cai P, Xie J, Wei Y. The diagnostic accuracy of digital PCR, ARMS and NGS for detecting KRAS mutation in cell-free DNA of patients with colorectal cancer: a systematic review and meta-analysis. PLoS One. 2021;16:e0248775.
Not in our library10.1371/journal.pone.0248775
118.
Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013;200:373-383.
Not in our library10.1083/jcb.201211138
119.
Sadik N, Cruz L, Gurtner A, Rodosthenous RS, Dusoswa SA, Ziegler O, Van Solinge TS, Wei Z, Salvador-Garicano AM, Gyorgy B, et al. Extracellular RNAs: a new awareness of old perspectives. Methods Mol Biol. 2018;1740:1-15.
Not in our library10.1007/978-1-4939-7652-2_1
120.
Detection of Extracellular Vesicle RNA Using Molecular Beacons · 2020
Not checked
121.
Gusachenko ON, Zenkova MA, Vlassov VV. Nucleic acids in exosomes: disease markers and intercellular communication molecules. Biochemistry (Mosc). 2013;78:1-7.
Not in our library10.1134/s000629791301001x
122.
Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30:255-289.
Not in our library10.1146/annurev-cellbio-101512-122326
123.
Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer · 2017
No notice
124.
Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano Y, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015;113:275-281.
Not in our library10.1038/bjc.2015.201
125.
Liu X, Pan B, Sun L, Chen X, Zeng K, Hu X, Xu T, Xu M, Wang S. Circulating Exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal Cancer. Cancer Epidemiol Biomark Prev. 2018;27:746-754.
Not in our library10.1158/1055-9965.epi-18-0067
126.
Wei R, Chen L, Qin D, Guo Q, Zhu S, Li P, Min L, Zhang S. Liquid biopsy of extracellular vesicle-derived miR-193a-5p in colorectal Cancer and discovery of its tumor-suppressor functions. Front Oncol. 2020;10:1372.
Not in our library10.3389/fonc.2020.01372
127.
Kou CH, Zhou T, Han XL, Zhuang HJ, Qian HX. Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer. Oncol Lett. 2016;12:4838-4844.
Not in our library10.3892/ol.2016.5265
128.
Zhao YJ, Song X, Niu L, Tang Y, Song X, Xie L. Circulating Exosomal miR-150-5p and miR-99b-5p as diagnostic biomarkers for colorectal Cancer. Front Oncol. 2019;9:1129.
Not in our library10.3389/fonc.2019.01129
129.
Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer · 2012
No notice
130.
Hu HY, Yu CH, Zhang HH, Zhang SZ, Yu WY, Yang Y, Chen Q. Exosomal miR-1229 derived from colorectal cancer cells promotes angiogenesis by targeting HIPK2. Int J Biol Macromol. 2019;132:470-477.
Not in our library10.1016/j.ijbiomac.2019.03.221
131.
Fu F, Jiang W, Zhou L, Chen Z. Circulating Exosomal miR-17-5p and miR-92a-3p predict pathologic stage and grade of colorectal Cancer. Transl Oncol. 2018;11:221-232.
Not in our library10.1016/j.tranon.2017.12.012
132.
Yan S, Han B, Gao S, Wang X, Wang Z, Wang F, Zhang J, Xu D, Sun B. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget. 2017;8:60149-60158.
Not in our library10.18632/oncotarget.18557
133.
Peng ZY, Gu RH, Yan B. Downregulation of exosome-encapsulated miR-548c-5p is associated with poor prognosis in colorectal cancer. J Cell Biochem. 2018;120:1457-1463.
Not in our library10.1002/jcb.27291
134.
Sun H, Meng Q, Shi C, Yang H, Li X, Wu S, Familiari G, Relucenti M, Aschner M, Wang X, Chen R. Hypoxia-inducible Exosomes facilitate liver-tropic Premetastatic niche in colorectal Cancer. Hepatology. 2021;74:2633-2651.
Not in our library10.1002/hep.32009
135.
Tanaka S, Hosokawa M, Miyamoto T, Nakagawa A, Haruna M, Ueda K, Iwakawa S, Ogawara KI. miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells. Biochem Biophys Rep. 2021;26:100996.
Not in our library10.1016/j.bbrep.2021.100996
136.
Ning T, Li J, He Y, Zhang H, Wang X, Deng T, Liu R, Li H, Bai M, Fan Q, et al. Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer. Mol Ther. 2021;29:2723-2736.
Not in our library10.1016/j.ymthe.2021.04.028
137.
Plasma Exosomal miRNA Expression Profile as Oxaliplatin-Based Chemoresistant Biomarkers in Colorectal Adenocarcinoma · 2020
Not checked
138.
Bjørnetrø T, Redalen KR, Meltzer S, Thusyanthan NS, Samiappan R, Jegerschöld C, Handeland KR, Ree AH. An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer. J Extracell Vesicles. 2019;8:1567219.
Not in our library10.1080/20013078.2019.1567219
139.
Ge L, Zhou F, Nie J, Wang X, Zhao Q. Hypoxic colorectal cancer-secreted exosomes deliver miR-210-3p to normoxic tumor cells to elicit a protumoral effect. Exp Biol Med (Maywood). 2021;246:1895-1906.
Not in our library10.1177/15353702211011576
140.
Hu D, Zhan Y, Zhu K, Bai M, Han J, Si Y, Zhang H, Kong D. Plasma Exosomal long non-coding RNAs serve as biomarkers for early detection of colorectal Cancer. Cell Physiol Biochem. 2018;51:2704-2715.
Not in our library10.1159/000495961
141.
Circulating Serum Exosomal Long Non-Coding RNAs FOXD2-AS1, NRIR, and XLOC_009459 as Diagnostic Biomarkers for Colorectal Cancer · 2021
Not checked
142.
Yin H, Hu J, Ye Z, Chen S, Chen Y. Serum long non-coding RNA NNT-AS1 protected by exosome is a potential biomarkerand functions as an oncogene via the miR-496/RAP2C axis in colorectal cancer. Mol Med Rep. 2021;24:585.
Not in our library10.3892/mmr.2021.12224
143.
Ren J, Ding L, Zhang D, Shi G, Xu Q, Shen S, Wang Y, Wang T, Hou Y. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. Theranostics. 2018;8:3932-3948.
Not in our library10.7150/thno.25541
144.
Deng X, Ruan H, Zhang X, Xu X, Zhu Y, Peng H, Zhang X, Kong F, Guan M. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. Int J Cancer. 2020;146:1700-1716.
Not in our library10.1002/ijc.32608
145.
Predictive role of UCA1-containing exosomes in cetuximab-resistant colorectal cancer · 2018
Not checked
146.
Exosomal Long Non-coding RNA HOTTIP Increases Resistance of Colorectal Cancer Cells to Mitomycin via Impairing MiR-214-Mediated Degradation of KPNA3 · 2021
Not checked
147.
Identification of Serum Exosomal hsa-circ-0004771 as a Novel Diagnostic Biomarker of Colorectal Cancer · 2019
No notice
148.
Li Y, Li C, Xu R, Wang Y, Li D, Zhang B. A novel circFMN2 promotes tumor proliferation in CRC by regulating the miR-1182/hTERT signaling pathways. Clin Sci (Lond). 2019;133:2463-2479.
Not in our library10.1042/cs20190715
149.
Hypoxia induced exosomal circRNA promotes metastasis of Colorectal Cancer via targeting GEF-H1/RhoA axis · 2020
No notice
150.
Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-β1 axis · 2020
No notice
151.
Zhao H, Chen S, Fu Q. Exosomes from CD133(+) cells carrying circ-ABCC1 mediate cell stemness and metastasis in colorectal cancer. J Cell Biochem. 2020;121:3286-3297.
Not in our library10.1002/jcb.29600
152.
Xu Y, Qiu A, Peng F, Tan X, Wang J, Gong X. Exosomal transfer of circular RNA FBXW7 ameliorates the chemoresistance to oxaliplatin in colorectal cancer by sponging miR-18b-5p. Neoplasma. 2021;68:108-118.
Not in our library10.4149/neo_2020_200417n414
153.
Zhao K, Cheng X, Ye Z, Li Y, Peng W, Wu Y, et al. Exosome-mediated transfer of circ_0000338 enhances 5-fluorouracil resistance in colorectal Cancer through regulating MicroRNA 217 (miR-217) and miR-485-3p. Mol Cell Biol. 2021;41(5):e00517–20.
Not in our library10.1128/mcb.00517-20
154.
Exosome‐delivered circRNA promotes glycolysis to induce chemoresistance through the miR‐122‐PKM2 axis in colorectal cancer · 2020
No notice
155.
Sun B, Li Y, Zhou Y, Ng TK, Zhao C, Gan Q, Gu X, Xiang J. Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer. J Cell Physiol. 2019;234:1416-1425.
Not in our library10.1002/jcp.26936
156.
Ganig N, Baenke F, Thepkaysone ML, Lin K, Rao VS, Wong FC, et al. Proteomic analyses of fibroblast- and serum-derived Exosomes identify QSOX1 as a marker for non-invasive detection of colorectal Cancer. Cancers (Basel). 2021;13(6):1351.
Not in our library10.3390/cancers13061351
157.
Yun CW, Lee JH, Go G, Jeon J, Yoon S, Lee SH. Prion protein of extracellular vesicle regulates the progression of colorectal Cancer. Cancers (Basel). 2021;13(9):2144.
Not in our library10.3390/cancers13092144
158.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-297.
Not in our library10.1016/s0092-8674(04)00045-5
159.
Detassis S, Grasso M, Del Vescovo V, Denti MA. microRNAs make the Call in Cancer personalized medicine. Front Cell Dev Biol. 2017;5:86.
Not in our library10.3389/fcell.2017.00086
160.
Suzuki HI, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene. 2015;34:3085-3094.
Not in our library10.1038/onc.2014.254
161.
Matsuzaki J, Ochiya T. Circulating microRNAs and extracellular vesicles as potential cancer biomarkers: a systematic review. Int J Clin Oncol. 2017;22:413-420.
Not in our library10.1007/s10147-017-1104-3
162.
Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, et al. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun. 2014;5:3591.
Not in our library10.1038/ncomms4591
163.
Alves Dos Santos K, Clemente Dos Santos IC, Santos Silva C, Gomes Ribeiro H, de Farias Domingos I, Nogueira Silbiger V. Circulating Exosomal miRNAs as Biomarkers for the Diagnosis and Prognosis of Colorectal Cancer. Int J Mol Sci. 2020;22(1):346.
Not in our library10.3390/ijms22010346
164.
Maleki M, Golchin A, Javadi S, Khelghati N, Morovat P, Asemi Z, et al. Role of exosomal miRNA in chemotherapy resistance of colorectal cancer: a systematic review. Chem Biol Drug Des. 2021. Online ahead of print.
Not in our library10.1111/cbdd.13947
165.
Cai J, Zuo X, Chen Z, Zhang Y, Wang J, Wang J, Ye X, Zhao W. Long noncoding RNAs serve as potential diagnostic biomarkers for colorectal Cancer. J Cancer. 2019;10:611-619.
Not in our library10.7150/jca.28780
166.
Serum long noncoding RNA HOTAIR as a novel diagnostic and prognostic biomarker in glioblastoma multiforme · 2018
No notice
167.
Oehme F, Krahl S, Gyorffy B, Muessle B, Rao V, Greif H, Ziegler N, Lin K, Thepkaysone ML, Polster H, et al. Low level of exosomal long non-coding RNA HOTTIP is a prognostic biomarker in colorectal cancer. RNA Biol. 2019;16:1339-1345.
Not in our library10.1080/15476286.2019.1637697
168.
Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther. 2018;187:31-44.
Not in our library10.1016/j.pharmthera.2018.01.010
169.
Salzman J. Circular RNA expression: its potential regulation and function. Trends Genet. 2016;32:309-316.
Not in our library10.1016/j.tig.2016.03.002
170.
Barrett SP, Salzman J. Circular RNAs: analysis, expression and potential functions. Development. 2016;143:1838-1847.
Not in our library10.1242/dev.128074
171.
Circular RNAs in cancer: an emerging key player · 2017
No notice
172.
Liu S, Wu M, Peng M. Circ_0000260 regulates the development and deterioration of gastric adenocarcinoma with cisplatin resistance by Upregulating MMP11 via targeting MiR-129-5p. Cancer Manag Res. 2020;12:10505-10519.
Not in our library10.2147/cmar.s272324
173.
Zhong Y, Wang D, Ding Y, Tian G, Jiang B. Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p. Biotechnol Lett. 2021;43:339-351.
Not in our library10.1007/s10529-020-03036-3
174.
Xu X, Tao R, Sun L, Ji X. Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway. Cancer Cell Int. 2020;20:552.
Not in our library10.1186/s12935-020-01642-9
175.
Exosomes Mediated Transfer of Circ_0000337 Contributes to Cisplatin (CDDP) Resistance of Esophageal Cancer by Regulating JAK2 via miR-377-3p · 2021
Not checked
176.
Zeng Z, Zhao Y, Chen Q, Zhu S, Niu Y, Ye Z, Hu P, Chen D, Xu P, Chen J, et al. Hypoxic exosomal HIF-1α-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis. Oncogene. 2021;40:5505-5517.
Not in our library10.1038/s41388-021-01960-w
177.
Zhao B, Li Z, Qin C, Li T, Wang Y, Cao H, Yang X, Wang W. Mobius strip in pancreatic cancer: biogenesis, function and clinical significance of circular RNAs. Cell Mol Life Sci. 2021;78:6201-6213.
Not in our library10.1007/s00018-021-03908-5
178.
Extracellular Vesicle-derived circular RNAs confers chemoresistance in Colorectal cancer · 2019
No notice
179.
Ding C, Yi X, Wu X, Bu X, Wang D, Wu Z, Zhang G, Gu J, Kang D. Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020;479:1-12.
Not in our library10.1016/j.canlet.2020.03.002
180.
Si J, Li W, Li X, Cao L, Chen Z, Jiang Z. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma. Cancer Sci. 2021;112:3491-3506.
Not in our library10.1111/cas.14984
181.
Pan Y, Lin Y, Mi C. Cisplatin-resistant osteosarcoma cell-derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801-dependent manner. Cell Biol Int. 2021;45:858-868.
Not in our library10.1002/cbin.11532
182.
Tu C, He J, Qi L, Ren X, Zhang C, Duan Z, Yang K, Wang W, Lu Q, Li Z. Emerging landscape of circular RNAs as biomarkers and pivotal regulators in osteosarcoma. J Cell Physiol. 2020;235:9037-9058.
Not in our library10.1002/jcp.29754
183.
Sandfeld-Paulsen B, Aggerholm-Pedersen N, Bæk R, Jakobsen KR, Meldgaard P, Folkersen BH, Rasmussen TR, Varming K, Jørgensen MM, Sorensen BS. Exosomal proteins as prognostic biomarkers in non-small cell lung cancer. Mol Oncol. 2016;10:1595-1602.
Not in our library10.1016/j.molonc.2016.10.003
184.
Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177-182.
Not in our library10.1038/nature14581
185.
Chen IH, Xue L, Hsu CC, Paez JS, Pan L, Andaluz H, Wendt MK, Iliuk AB, Zhu JK, Tao WA. Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci U S A. 2017;114:3175-3180.
Not in our library10.1073/pnas.1618088114
186.
Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382-386.
Not in our library10.1038/s41586-018-0392-8
187.
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory · 2019
No notice
188.
Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019;88:487-514.
Not in our library10.1146/annurev-biochem-013118-111902
189.
Wang W, Luo J, Wang S. Recent Progress in isolation and detection of extracellular vesicles for Cancer diagnostics. Adv Healthc Mater. 2018;7:e1800484.
Not in our library10.1002/adhm.201800484
190.
Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in Exosome Isolation Techniques Theranostics. 2017;7:789-804.
Not in our library10.7150/thno.18133
191.
Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820:940-948.
Not in our library10.1016/j.bbagen.2012.03.017
192.
Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey · 2016
Not checked
193.
Petersen KE, Manangon E, Hood JL, Wickline SA, Fernandez DP, Johnson WP, Gale BK. A review of exosome separation techniques and characterization of B16-F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-TEM. Anal Bioanal Chem. 2014;406:7855-7866.
Not in our library10.1007/s00216-014-8040-0
194.
Taylor DD, Shah S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods. 2015;87:3-10.
Not in our library10.1016/j.ymeth.2015.02.019
195.
Musante L, Tataruch DE, Holthofer H. Use and isolation of urinary exosomes as biomarkers for diabetic nephropathy. Front Endocrinol (Lausanne). 2014;5:149.
Not in our library10.3389/fendo.2014.00149
196.
Isolation of anti-extra-cellular vesicle single-domain antibodies by direct panning on vesicle-enriched fractions · 2018
Not checked
197.
Tauro BJ, Greening DW, Mathias RA, Ji H, Mathivanan S, Scott AM, Simpson RJ. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods. 2012;56:293-304.
Not in our library10.1016/j.ymeth.2012.01.002
198.
Wu M, Ouyang Y, Wang Z, Zhang R, Huang PH, Chen C, Li H, Li P, Quinn D, Dao M, et al. Isolation of exosomes from whole blood by integrating acoustics and microfluidics. Proc Natl Acad Sci U S A. 2017;114:10584-10589.
Not in our library10.1073/pnas.1709210114
199.
Ibsen SD, Wright J, Lewis JM, Kim S, Ko SY, Ong J, Manouchehri S, Vyas A, Akers J, Chen CC, et al. Rapid isolation and detection of Exosomes and associated biomarkers from plasma. ACS Nano. 2017;11:6641-6651.
Not in our library10.1021/acsnano.7b00549
200.
Ranjan S, Zeming KK, Jureen R, Fisher D, Zhang Y. DLD pillar shape design for efficient separation of spherical and non-spherical bioparticles. Lab Chip. 2014;14:4250-4262.
Not in our library10.1039/c4lc00578c
201.
Liu C, Yang Y, Wu Y. Recent advances in Exosomal protein detection via liquid biopsy biosensors for Cancer screening, diagnosis, and prognosis. AAPS J. 2018;20:41.
Not in our library10.1208/s12248-018-0201-1
202.
Saad MG, Beyenal H, Dong WJ. Exosomes as powerful Engines in Cancer: isolation, Characterization and Detection Techniques. Biosensors (Basel). 2021;11(12):518.
Not in our library10.3390/bios11120518
203.
Lin S, Yu Z, Chen D, Wang Z, Miao J, Li Q, Zhang D, Song J, Cui D. Progress in microfluidics-based exosome separation and detection Technologies for Diagnostic Applications. Small. 2020;16:e1903916.
Not in our library10.1002/smll.201903916
204.
Xu L, Shoaie N, Jahanpeyma F, Zhao J, Azimzadeh M, Al Jamal KT. Optical, electrochemical and electrical (nano)biosensors for detection of exosomes: a comprehensive overview. Biosens Bioelectron. 2020;161:112222.
Not in our library10.1016/j.bios.2020.112222
205.
Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell. 2020;181:151-167.
Not in our library10.1016/j.cell.2020.02.001
206.
Plantureux L, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C. Effects of platelets on cancer progression. Thromb Res. 2018;164(Suppl 1):S40-s47.
Not in our library10.1016/j.thromres.2018.01.035
207.
Peterson JE, Zurakowski D, Italiano JE, Michel LV, Connors S, Oenick M, D'Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis. 2012;15:265-273.
Not in our library10.1007/s10456-012-9259-z
208.
Plantureux L, Mège D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Impacts of Cancer on platelet production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis. Cancers (Basel). 2018;10(11):441.
Not in our library10.3390/cancers10110441
209.
Best MG, Wesseling P, Wurdinger T. Tumor-educated platelets as a noninvasive biomarker source for Cancer detection and progression monitoring. Cancer Res. 2018;78:3407-3412.
Not in our library10.1158/0008-5472.can-18-0887
210.
Lood C, Amisten S, Gullstrand B, Jönsen A, Allhorn M, Truedsson L, Sturfelt G, Erlinge D, Bengtsson AA. Platelet transcriptional profile and protein expression in patients with systemic lupus erythematosus: up-regulation of the type I interferon system is strongly associated with vascular disease. Blood. 2010;116:1951-1957.
Not in our library10.1182/blood-2010-03-274605
211.
Olsson AK, Cedervall J. The pro-inflammatory role of platelets in cancer. Platelets. 2018;29:569-573.
Not in our library10.1080/09537104.2018.1453059
212.
Xue L, Xie L, Song X, Song X. Identification of potential tumor-educated platelets RNA biomarkers in non-small-cell lung cancer by integrated bioinformatical analysis. J Clin Lab Anal. 2018;32:e22450.
Not in our library10.1002/jcla.22450
213.
Sheng M, Dong Z, Xie Y. Identification of tumor-educated platelet biomarkers of non-small-cell lung cancer. Onco Targets Ther. 2018;11:8143-8151.
Not in our library10.2147/ott.s177384
214.
Luo CL, Xu ZG, Chen H, Ji J, Wang YH, Hu W, Wang K, Zhang WW, Yuan CH, Wang FB. LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis. Cancer Manag Res. 2018;10:1449-1459.
Not in our library10.2147/cmar.s164227
215.
Goswami C, Chawla S, Thakral D, Pant H, Verma P, Malik PS. Jayadeva, Gupta R, Ahuja G, Sengupta D: molecular signature comprising 11 platelet-genes enables accurate blood-based diagnosis of NSCLC. BMC Genomics. 2020;21:744.
Not in our library10.1186/s12864-020-07147-z
216.
Dong X, Song X, Ding S, Yu M, Shang X, Wang K, Chang M, Xie L, Song X. Tumor-educated platelet SNORD55 as a potential biomarker for the early diagnosis of non-small cell lung cancer. Thorac Cancer. 2021;12:659-666.
Not in our library10.1111/1759-7714.13823
217.
Waqar W, Asghar S, Manzoor S. Platelets' RNA as biomarker trove for differentiation of early-stage hepatocellular carcinoma from underlying cirrhotic nodules. PLoS One. 2021;16:e0256739.
Not in our library10.1371/journal.pone.0256739
218.
Asghar S, Waqar W, Umar M, Manzoor S. Tumor educated platelets, a promising source for early detection of hepatocellular carcinoma: liquid biopsy an alternative approach to tissue biopsy. Clin Res Hepatol Gastroenterol. 2020;44:836-844.
Not in our library10.1016/j.clinre.2020.03.023
219.
Best MG, Wurdinger T. Tumor-educated platelets for the earlier detection of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2020;44:794-795.
Not in our library10.1016/j.clinre.2020.03.028
220.
Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma · 2020
Not checked
221.
Campanella R, Guarnaccia L, Cordiglieri C, Trombetta E, Caroli M, Carrabba G, et al. Tumor-educated platelets and angiogenesis in glioblastoma: another brick in the wall for novel prognostic and targetable biomarkers, changing the vision from a localized tumor to a systemic pathology. Cells. 2020;9(2):294.
Not in our library10.3390/cells9020294
222.
Mendoza-Almanza G, Burciaga-Hernández L, Maldonado V, Melendez-Zajgla J, Olmos J. Role of platelets and breast cancer stem cells in metastasis. World J Stem Cells. 2020;12:1237-1254.
Not in our library10.4252/wjsc.v12.i11.1237
223.
Plantureux L, Mège D, Crescence L, Carminita E, Robert S, Cointe S, Brouilly N, Ezzedine W, Dignat-George F, Dubois C, Panicot-Dubois L. The interaction of platelets with colorectal Cancer cells inhibits tumor growth but promotes metastasis. Cancer Res. 2020;80:291-303.
Not in our library10.1158/0008-5472.can-19-1181
224.
Tesfamariam B. Involvement of platelets in tumor cell metastasis. Pharmacol Ther. 2016;157:112-119.
Not in our library10.1016/j.pharmthera.2015.11.005
225.
Yang L, Jiang Q, Li DZ, Zhou X, Yu DS, Zhong J. TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer. Aging (Albany NY). 2019;11:8998-9012.
Not in our library10.18632/aging.102366
226.
Qian W, Ge XX, Wu J, Gong FR, Wu MY, Xu MD, Lian L, Wang WJ, Li W, Tao M. Prognostic evaluation of resectable colorectal cancer using platelet-associated indicators. Oncol Lett. 2019;18:571-580.
Not in our library10.3892/ol.2019.10388
227.
Rowley JW, Weyrich AS. Coordinate expression of transcripts and proteins in platelets. Blood. 2013;121:5255-5256.
Not in our library10.1182/blood-2013-03-487991
228.
Lasham A, Fitzgerald SJ, Knowlton N, Robb T, Tsai P, Black MA, Williams L, Mehta SY, Harris G, Shelling AN, et al. A predictor of early disease recurrence in patients with breast Cancer using a cell-free RNA and protein liquid biopsy. Clin Breast Cancer. 2020;20:108-116.
Not in our library10.1016/j.clbc.2019.07.003
229.
Olmedillas-López S, García-Arranz M, García-Olmo D. Current and emerging applications of droplet digital PCR in oncology. Mol Diagn Ther. 2017;21:493-510.
Not in our library10.1007/s40291-017-0278-8
230.
Herrera M, Galindo-Pumariño C, García-Barberán V, Peña C. A snapshot of the tumor microenvironment in colorectal Cancer: the liquid biopsy. Int J Mol Sci. 2019;20.
Not in our library10.3390/ijms20236016
231.
Galindo-Pumariño C, Collado M, Herrera M, Peña C. Tumor microenvironment in metastatic colorectal Cancer: the arbitrator in Patients' outcome, vol. 13. Cancers (Basel). 2021.
Not in our library10.3390/cancers13051130
232.
Circulating Endothelial Cells, Endothelial Progenitor Cells, and Endothelial Microparticles in Cancer · 2006
Not checked
233.
Bethel K, Luttgen MS, Damani S, Kolatkar A, Lamy R, Sabouri-Ghomi M, Topol S, Topol EJ, Kuhn P. Fluid phase biopsy for detection and characterization of circulating endothelial cells in myocardial infarction. Phys Biol. 2014;11:016002.
Not in our library10.1088/1478-3975/11/1/016002
234.
Zhu Y, Zhu J, Tian X, Zhang F, Zhao L, Zhu J, Lv K, Yang N, Wang C. Circulating endothelial progenitor cells from septic patients are associated with different infectious organisms. Ann Palliat Med. 2021;10:549-559.
Not in our library10.21037/apm-20-2458
235.
Nizzoli ME, Merati G, Tenore A, Picone C, Consensi E, Perotti L, Ferretti VV, Sambo M, Di Sabatino A, Iotti GA, et al. Circulating endothelial cells in COVID-19. Am J Hematol. 2020;95:E187-e188.
Not in our library10.1002/ajh.25881
236.
Duong HT, Erzurum SC, Asosingh K. Pro-angiogenic hematopoietic progenitor cells and endothelial colony-forming cells in pathological angiogenesis of bronchial and pulmonary circulation. Angiogenesis. 2011;14:411-422.
Not in our library10.1007/s10456-011-9228-y
237.
Manzoni M, Comolli G, Torchio M, Mazzini G, Danova M. Circulating endothelial cells and their subpopulations: role as predictive biomarkers in antiangiogenic therapy for colorectal cancer. Clin Colorectal Cancer. 2015;14:11-17.
Not in our library10.1016/j.clcc.2014.12.002
238.
Rahbari NN, Schölch S, Bork U, Kahlert C, Schneider M, Rahbari M, Büchler MW, Weitz J, Reissfelder C. Prognostic value of circulating endothelial cells in metastatic colorectal cancer. Oncotarget. 2017;8:37491-37501.
Not in our library10.18632/oncotarget.16397
239.
Cima I, Kong SL, Sengupta D, Tan IB, Phyo WM, Lee D, Hu M, Iliescu C, Alexander I, Goh WL, et al. Tumor-derived circulating endothelial cell clusters in colorectal cancer. Sci Transl Med. 2016;8:345ra389.
Not in our library10.1126/scitranslmed.aad7369
240.
Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, Rovati B, Tinelli C, Falcone A, Villa E, Danova M. Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol. 2010;21:2382-2389.
Not in our library10.1093/annonc/mdq261
241.
Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, François E, et al. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol. 2012;23:919-927.
Not in our library10.1093/annonc/mdr365
242.
Matsusaka S, Mishima Y, Suenaga M, Terui Y, Kuniyoshi R, Mizunuma N, Hatake K. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer. 2011;117:4026-4032.
Not in our library10.1002/cncr.25977
243.
Gootjes EC, Kraan J, Buffart TE, Bakkerus L, Zonderhuis BM, Verhoef C, et al. CD276 positive circulating endothelial cells do not predict response to systemic therapy in advanced colorectal Cancer. Cells. 2020;9(1):124.
Not in our library10.3390/cells9010124
244.
Lin PP. Aneuploid CTC and CEC. Diagnostics (Basel). 2018;8(2):26.
Not in our library10.3390/diagnostics8020026
245.
Roselli M, Formica V, Cereda V, Jochems C, Richards J, Grenga I, Orlandi A, Ferroni P, Guadagni F, Schlom J. The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. Oncoimmunology. 2016;5:e1188243.
Not in our library10.1080/2162402x.2016.1188243
246.
Bencsikova B, Budinska E, Selingerova I, Pilatova K, Fedorova L, Greplova K, Nenutil R, Valik D, Obermannova R, Sheard MA, Zdrazilova-Dubska L. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness. BMC Cancer. 2019;19:687.
Not in our library10.1186/s12885-019-5909-5
247.
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer · 2016
No notice
248.
Chang J, Lin G, Ye M, Tong D, Zhao J, Zhu D, Yu Q, Zhang W, Li W. Decreased mean platelet volume predicts poor prognosis in metastatic colorectal cancer patients treated with first-line chemotherapy: results from mCRC biomarker study. BMC Cancer. 2019;19:15.
Not in our library10.1186/s12885-018-5252-2
249.
Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018;29:924-930.
Not in our library10.1093/annonc/mdy004
250.
Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease. Eur J Surg Oncol. 2006;32:756-763.
Not in our library10.1016/j.ejso.2006.03.028
251.
Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology · 2019
No notice
252.
Heidrich I, Ackar L, Mohammadi PM, Pantel K. Liquid biopsies: potential and challenges. Int J Cancer. 2021;148:528-545.
Not in our library10.1002/ijc.33217
253.
Kilgour E, Rothwell DG, Brady G, Dive C. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell. 2020;37:485-495.
Not in our library10.1016/j.ccell.2020.03.012
254.
Biswas D, Ganeshalingam J, Wan JCM. The future of liquid biopsy. Lancet Oncol. 2020;21:e550.
Not in our library10.1016/s1470-2045(20)30687-2
255.
ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress · 2018
No notice
256.
Ding Y, Li W, Wang K, Xu C, Hao M, Ding L. Perspectives of the application of liquid biopsy in colorectal Cancer. Biomed Res Int. 2020;2020:6843180.
Not in our library10.1155/2020/6843180
257.
Sol N, Wurdinger T. Platelet RNA signatures for the detection of cancer. Cancer Metastasis Rev. 2017;36:263-272.
Not in our library10.1007/s10555-017-9674-0
258.
Best MG, Vancura A, Wurdinger T. Platelet RNA as a circulating biomarker trove for cancer diagnostics. J Thromb Haemost. 2017;15:1295-1306.
Not in our library10.1111/jth.13720

Cited by papers we hold 6

Tumor biomarkers for diagnosis, prognosis and targeted therapy · 2024
No notice
Pre-metastatic niche: formation, characteristics and therapeutic implication · 2024
No notice
Role of Epithelial to Mesenchymal Transition in Colorectal Cancer · 2023
No notice
Clinical application and detection techniques of liquid biopsy in gastric cancer · 2023
No notice
Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation · 2023
No notice
Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.